Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Objectives: To report pooled safety/tolerability and seizure outcome data from adults with uncontrolled partial‐onset (focal) seizures (POS) receiving adjunctive brivaracetam (BRV) during phase IIb/III and long‐term follow‐up (LTFU) studies. Methods: Seizure outcome data were pooled from phase IIb (NCT00175929 and NCT00175825), III/IIIb (NCT00490035, NCT00464269, NCT00504881, and NCT01261325) and associated LTFU studies (NCT00175916, NCT00150800, and NCT01339559). Safety/tolerability data were pooled from these studies plus NCT01405508, NCT01653262, and NCT01728077 (LTFU). Patients received placebo (during core studies) or BRV 5–200 mg/day. Safety/tolerability and seizure outcomes (BRV modal doses 50–200 mg/day) were assessed until January 17, 2014. Results: Of 2,186 patients (97.3% with POS and 2.7% with other seizure types) who received BRV 50–200 mg/day, 2,051 (93.8%) completed core studies and continued in LTFU studies. Total BRV exposure: 5,339.4 patient‐years (≥8.0 years in 41 patients); 6‐, 12‐, 24‐, and 60‐month retention: 91.0%, 79.8%, 68.1%, and 54.4%, respectively. Safety/tolerability data pooled from 2,186 patients: ≥1 treatment‐emergent adverse event (TEAE) reported by 1,848 (84.5%) patients; 1,184 (54.2%) reported ≥1 TEAE considered treatment‐related. Most frequent TEAEs (≥10%): headache (20.9%), dizziness (17.5%), somnolence (15.2%), nasopharyngitis (13.2%), fatigue (11.3%), and convulsion (10.6%). Serious TEAEs (SAEs) and treatment‐related SAEs: 401 (18.3%) and 95 (4.3%) patients, respectively. Of 28 (1.3%) deaths, four (14.3%) were considered possibly treatment related by the investigator. Pooled seizure outcome data (1,836 patients): median POS frequency/28 days at baseline was 8.9; on treatment, median percentage reduction from baseline in POS/28 days was 48.8%, and ≥50% responder rate was 48.7%. Complete seizure freedom: 4.9%, 4.2%, 3.0%, and 3.3% for ≥6, 12, 24, and 60 months, respectively. Improvements were seen in health‐related quality of life (HRQoL) from baseline, assessed by Quality of Life in Epilepsy Inventory‐31. Significance: Adjunctive BRV treatment in adults with POS was effective and generally well tolerated when administered long‐term (≥8.0 years). Retention was high and HRQoL improvements were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory
Cramer, J. A., Perrine, K., Devinsky, O., Bryant‐Comstock, L., Meador, K., & Hermann, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01278.x · Cited by 782
Cited by
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
Self-citationKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“Efficacy and tolerability of BRV treatment in adults with focal-onset seizures was also confirmed in a pooled analysis of > 2000 patients receiving BRV 50–200 mg/day during the phase IIb and phase III trials and their associated long-term follow-up trials [40].”
A brief review on efficacy and safety of brivaracetam in the management of partial onset epilepsy
Vithoba Panchal, G., & Nath Mishra, V. (2021) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2021.017 · Cited by 2
Metadata
- Authors
- Toledo, M., Whitesides, J., Schiemann, J., Johnson, M. E., Eckhardt, K., McDonough, B., Borghs, S., & Kwan, P.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2016-06-06
- Volume
- 57
- Issue
- 7
- Pages
- 1139-1151
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2419659369
- Cited by
- 75
- References
- 1
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.